For management of grade 3 and higher hematologic adverse events, such as leukopenia and neutropenia, recombinant-human granulocyte colony-stimulating factor could be applied; therefore, these severe hematologic adverse events could be controlled and handled (Bian, et al., 2019). The gene discussed is CSF3; the disease is Decreased total neutrophil count.